the article talks about a company named Boston Scientific that makes medical equipment. They will be reporting their financial results for the second quarter of the year soon. Analysts think they will have sold more of their WATCHMAN product, which is used to help treat heart problems, and that this will help the company's earnings. Earnings are like the money report for how well the company did during that time period. Read from source...

In the article titled `Will WATCHMAN Sales Aid Boston Scientific's Q2 Earnings?` published on July 17, 2024, Zacks discusses Boston Scientific's upcoming Q2 earnings report. According to Zacks, the company is expected to report strong sales results for the quarter, particularly in the WATCHMAN subsegment within the Cardiovascular division. Despite challenges such as a challenging supply environment in some geographies and surging labor and raw material costs, the company has shown continued growth in every geographic region. The article provides detailed information on Boston Scientific's expected revenue growth, earnings per share, and sales results by business segment. Overall, the article provides a thorough analysis of Boston Scientific's Q2 earnings potential, citing factors such as innovative product pipelines, globalization efforts, and enhanced digital capabilities as contributing to the company's continued success.

The article discusses Boston Scientific's upcoming Q2 earnings report, with estimates suggesting revenue growth and increased earnings per share. While factors such as challenging supply environments and rising labor and material costs may impact results, the company's strong performance in recent quarters and geographic expansion suggests a potential for solid sales. The consensus estimate for WATCHMAN revenues indicates significant growth. The overall sentiment of the article can be considered bullish, as it highlights the potential for positive results in Boston Scientific's upcoming earnings report.

1. Boston Scientific Corporation (BSX) is expected to report decent sales results for the second quarter of 2024. The Zacks Consensus Estimate for second-quarter total revenues is pegged at $4.02 billion, suggesting an improvement of 11.7% from the prior- year quarter's reported number. The consensus mark for adjusted earnings stands at 58 cents per share, implying a 9.4% rise from the year-ago quarter's reported figure.

Risks: The rate of growth is expected to have remained sluggish amid a challenging supply environment in limited geographies. Further, the business is expected to have faced the hurdle of surging labor and raw material costs, as well as healthcare staffing shortages, which might have weighed on the bottom line in the second quarter.

2. WATCHMAN sales within the Cardiovascular division have shown meaningful strength in recent times and are expected to report strong growth in the second quarter on sustained momentum from second-generation WATCHMAN FLX, ongoing clinical evidence, globalization, and commercial execution.

Risks: Although the WATCHMAN subsegment shows strength, the overall market is challenging with surging labor and raw material costs, and healthcare staffing shortages.

3. National Vision EYE, Glaukos GKOS, and Tandem Diabetes TNDM are stocks that investors could consider as they have the potential to post an earnings beat this quarter.

Risks: As with any investment, there are risks involved. The market is unpredictable and can change rapidly, affecting the performance of stocks.